newsfilter
← Latest News
GlobeNewswire·

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in cash at